PRN 1008

Drug Profile

PRN 1008

Alternative Names: PRN-1008

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Principia Biopharma
  • Class Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pemphigus vulgaris
  • Phase I Autoimmune disorders

Most Recent Events

  • 18 Sep 2017 Interim efficacy and adverse events data from a phase II trial in Pemphigus vulgaris released by Principia Biopharma
  • 11 Jul 2017 PRN 1008 receives Orphan Drug status for Pemphigus vulgaris in USA
  • 28 Oct 2016 Principia Biopharma completes a phase I pharmacokinetics trial in Healthy volunteers in Australia (PO, Tablet) (ACTRN12616001557426)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top